Imago BioSciences, Inc. Common stock
IMGO
IMGO was delisted on the 10th of January, 2023.
0 hedge funds and large institutions have $0 invested in Imago BioSciences, Inc. Common stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 105 closing their positions.
100% less funds holding
Funds holding: 106 → 0 (-106)
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $1.05B → $0 (-$1.05B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 105
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$161M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$143M |
| 3 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$109M |
| 4 |
Blackstone Inc
New York
|
-$85.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$45.5M |
IMGO Hedge Fund Activity: Q1 2023 in Review
0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences, Inc. Common stock (IMGO) for Q1 2023, worth a combined $0 — down 100% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 105 funds closed out of IMGO and 0 opened new positions — a net loss of 105 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $161M sold.
- 0 institutional investors held Imago BioSciences, Inc. Common stock (IMGO) as of Q1 2023, down from 106 in Q4 2022.
- Funds reported $0 of Imago BioSciences, Inc. Common stock stock for Q1 2023, down 100% quarter-over-quarter.
- 0 funds opened new Imago BioSciences, Inc. Common stock positions in Q1 2023 and 105 closed out, a net change of -105 holders.
- The largest Imago BioSciences, Inc. Common stock seller in Q1 2023 was BlackRock, an estimated $161M sold.
Based on aggregated 13F filings for Q1 2023.